Comparing timing for resuming blood thinners after polyp removal
Timing of Resumption of Direct Oral Anticoagulants Following Colonoscopy Polypectomy: a Prospective Randomized Non-inferiority Trial
NA · The University of Hong Kong · NCT06482333
This study is testing whether it's safe for people on blood thinners to start taking them again right after having polyps removed during a colonoscopy, compared to waiting two days.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 194 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | The University of Hong Kong (other) |
| Locations | 1 site (Hong Kong) |
| Trial ID | NCT06482333 on ClinicalTrials.gov |
What this trial studies
This prospective randomized trial aims to evaluate the safety of resuming Direct Oral Anticoagulants (DOACs) either on the same day or two days after colonoscopic polypectomy. Patients will be randomly assigned to one of two groups: one group will resume DOACs immediately after the procedure, while the other will wait for two days. The study will assess the rates of post-polypectomy bleeding in both groups to determine if early resumption is as safe as delayed resumption. All procedures will be performed by experienced endoscopists following a standardized polypectomy protocol.
Who should consider this trial
Good fit: Ideal candidates are adult patients on DOACs scheduled for elective colonoscopy with polypectomy.
Not a fit: Patients with prior colonic resections, inflammatory bowel disease, or those requiring advanced polypectomy techniques will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could help optimize anticoagulant management for patients undergoing polypectomy, reducing the risk of bleeding complications.
How similar studies have performed: While similar studies have explored anticoagulant management, this specific comparison of resumption timing after polypectomy is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- All adult patients who are taking DOACs and schedule for elective colonoscopy are potentially eligible. We only included patients who had complete colonoscopy and with polypectomy performed. Exclusion Criteria: * Previous resection of any colonic segments, * Inflammatory bowel disease or polyposis syndrome * Patient with large polyp required advanced procedure e.g. endoscopic submucosal dissection (ESD) to remove * Patients who develop immediate post-polypectomy bleeding during the procedure and requiring haemostasis will also be excluded * Patient without polypectomy * Patient without complete colonoscopy done
Where this trial is running
Hong Kong
- Queen Mary Hospital, the University of Hong Kong — Hong Kong, Hong Kong (RECRUITING)
Study contacts
- Principal investigator: Wai Keung Leung — The University of Hong Kong
- Study coordinator: Wai Keung Leung
- Email: waikleung@hku.hk
- Phone: +852 22553348
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Postpolypectomy Bleeding, Postpolypectomy bleeding,, DOAC, Colonoscopy